Healthcare upgrades, downgrades, and initiations for Friday


Ironwood Pharmaceuticals (IRWD +4.9%) upgraded to Outperform from Market Perform at BMO. Price target is $16.

Bristol-Myers Squibb (BMY +0.7%upgraded to Overweight from Equalweight at Barclays. Price target hiked to $65 from $52.

Sequenom (SQNM -3.4%) cut to Neutral from Overweight at Piper. Price target is $2.50.

BioMarin (BMRN -2.2%cut to Equalweight from Overweight at Barclays. Price target is $73.

Johnson & Johnson (JNJ -0.5%cut to Equalweight from Overweight at Barclays. Price target is $99.

Pfizer (PFE -0.6%cut to Market Perform at Cowen. Price target is $34.

Eli Lilly (LLY -0.4%) downgraded to Underweight from Equalweight at Barclays. Price target cut to $51 from $58.

H.C. Wainwright starts Celsion (CLSN +7.7%) at Buy. Price target is $8.

Orexigen (OREX +1.1%initiated at Buy with a $9 target at Wallachbeth.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs